Inhibitory effect of baicalin and baicalein on ovarian cancer cells

International Journal of Molecular Sciences

Volumn 14, Issue 3, 2013, Pages 6012-6025

  Chen, Jianchu ^a,b   Li, Zhaoliang ^b   Chen, Allen Y ^c   Ye, Xingqian ^a   Luo, Haitao ^b   Rankin, Gary O ^d   Chen, Yi Charlie ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b Alderson Broaddus College   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

^d MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Baicalein; Baicalin; Cell viability; HIF 1a; Ovarian cancer; VEGF

Indexed keywords

BAICALEIN; BAICALIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN KINASE B; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL STRAIN CP 70; CELL STRAIN OVCAR 3; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INCUBATION TIME; LD 50; OVARY CANCER; OVARY CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84875540393     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14036012     Document Type: Article

References (33)

1. Jemal, A.; Tiwari, R.C.; Murray, T.; Ghafoor, A.; Samuels, A.; Ward, E.; Feuer, E.J.; Thun, M.J. Cancer statistics, 2004. CA Cancer J. Clin. 2004, 54, 8-29.
2. Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; Thun, M. Cancer statistics. CA Cancer J. Clin. 2001, 51, 15-36.
3. Sarojini, S.; Tamir, A.; Lim, H.; Li, S.; Zhang, S.; Goy, A.; Pecora, A.; Suh, K.S. Early detection biomarkers for ovarian cancer. J. Oncol. 2012, 2012, 709049.
4. McGuire, W.P.; Hoskins, W.J.; Brady, M.F.; Kucera, P.R.; Partridge, E.E.; Look, K.Y.; Clarke-Pearson, D.L.; Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996, 334, 1-6.
5. Eckstein, N. Platinum resistance in breast and ovarian cancer cell lines. J. Exp. Clin. Cancer Res. 2011, 30, 91.
6. Bosetti, C.; Rossi, M.; McLaughlin, J.K.; Negri, E.; Talamini, R.; Laqiou, P.; Montella, M.; Ramazzotti, V.; Franceschi, S.; LaVecchia, C. Flavonoids and the risk of renal cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 98-101.
7. Gonzalez, C.A.; Riboli, E. Diet and cancer prevention: where we are, where we are going. Nutr. Cancer 2006, 56, 225-231.
8. Holick, C.N.; Giovannucci, E.L.; Rosner, B.; Stampfer, M.J.; Michaud, D.S. Prospective study of intake of fruit, vegetables, and carotenoids and the risk of adult glioma. Am. J. Clin. Nutr. 2007, 85, 877-886.
9. Mink, P.J.; Scrafford, C.G.; Barraj, L.M.; Harnack, L.; Hong, C.P.; Nettleton, J.A.; Jacobs, D.R., Jr. Flavonoid intake and cardiovascular disease mortality: A prospective study in postmenopausal women. Am. J. Clin. Nutr. 2007, 85, 895-909.
10. Nishida, N.; Yano, H.; Komai, K.; Nishida, T.; Kamura, T.; Kojiro, M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004, 101, 1364-1374.
11. Bosetti, C.; Bravi, F.; Talamini, R.; Parpinel, M.; Gnagnarella, P.; Negri, E.; Montella, M.; Lagiou, P.; Franceschi, S.; LaVecchia, C. Flavonoids and prostate cancer risk: A study in Italy. Nutr. Cancer 2006, 56, 123-127.
12. Theodoratou, E.; Kyle, J.; Cetnarskyj, R.; Farrington, S.M.; Tenesa, A.; Barnetson, R.; Porteous, M.; Dunlop, M.; Campbell, H. Dietary flavonoids and the risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 684-693.
13. Chao, J.I.; Su, W.C.; Liu, H.F. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol. Cancer Ther. 2007, 6, 3039-3048.
14. Chen, S.S.; Michael, A.; Butler-Manuel, S.A. Advances in the treatment of ovarian cancer: A potential role of antiinflammatory phytochemicals. Discov. Med. 2012, 13, 7-17.
15. Luo, H.; Rankin, G.O.; Liu, L.; Daddysman, M.K.; Jiang, B.H.; Chen, Y.C. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr. Cancer 2009, 61, 554-563.
16. Luo, H.; Rankin, G.O.; Juliano, N.; Jiang, B.H.; Chen, Y.C. Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway. Food Chem. 2012, 130, 321-328.
17. Plochmann, K.; Korte, G.; Koutsilieri, E.; Richling, E.; Riederer, P.; Rethwilm, A.; Schreier, P.; Scheller, C. Structure-Activity relationships of flavonoid-induced cytotoxicity on human leukemia cells. Arch. Biochem. Biophys. 2007, 460, 1-9.
18. Choi, E.J.; Kim, T.; Lee, M.S. Pro-Apoptotic effect and cytotoxicity of genistein and genistin in human ovarian cancer SK-OV-3 cells. Life Sci. 2007, 80, 1403-1408.
19. Franek, K.J.; Zhou, Z.; Zhang, W.D.; Chen, W.Y. In vitro studies of baicalin alone or in combination with Salvia miltiorrhiza extract as a potential anti-cancer agent. Int. J. Oncol. 2005, 26, 217-224.
20. Banks, E. The Epidemiology of Ovarian Cancer. In Ovarian Cancer Methods and Protocols; Bartlett, J.M.S., Ed.; Humana Press: Totowa, NJ, USA, 2000; pp. 3-6.
21. Pan, S.Y.; Ugnat, A.M.; Mao, Y.; Wen, S.W.; Johnson, K.C.; Canadian Cancer Registries Epidemiology Research Group. A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1521-1527.
22. Gates, M.A.; Tworoger, S.S.; Hecht, J.L.; de Vivo, I.; Rosner, B.; Hankinson, S.E. A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int. J. Cancer 2007, 121, 2225-2232.
23. Ikezoe, T.; Chen, S.S.; Heber, D.; Taguchi, H.; Koeffler, H.P. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 2001, 49, 285-292.
24. Li-Weber, M. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev. 2009, 35, 57-68.
25. Li, L.; Zeng, H.; Shan, L.; Yuan, X.; Li, Y.; Liu, R.; Zhang, W. The different inhibitory effects of Huang-Lian-Jie-Du-Tang on cyclooxygenase 2 and 5-lipoxygenase. J. Ethnopharmacol. 2012, 143, 732-739.
26. Cheng, Y.H.; Li, L.A.; Lin, P.; Cheng, L.C.; Hung, C.H.; Chang, N.W.; Lin, C. Baicalein induces G1 arrest in oral cancer cells by enhancing the degradation of cyclin D1 and activating AhR to decrease Rb phosphorylation. Toxicol. Appl. Pharmacol. 2012, 263, 360-367.
27. Ling, Y.; Chen, Y.; Chen, P.; Hui, H.; Song, X.; Lu, Z.; Li, C.; Lu, N.; Guo, Q. Baicalein potently suppresses angiogenesis induced by vascular endothelial growth factor through the p53/Rb signaling pathway leading to G1/S cell cycle arrest. Exp. Biol. Med. (Maywood) 2011, 236, 851-858.
28. Zhang, K.; Lu, J.; Mori, T.; Smith-Powell, L.; Synold, T.W.; Chen, S.; Wen, W. Baicalin increases VEGF expression and angiogenesis by activating the ERRα/PGC-1α pathway. Cardiovasc. Res. 2011, 89, 426-435.
29. Hwang, K.Y.; Oh, Y.T.; Yoon, H.; Lee, J.; Kim, H.; Choe, W.; Kang, I. Baicalein suppresses hypoxia-induced HIF-1alpha protein accumulation and activation through inhibition of reactive oxygen species and PI 3-kinase/Akt pathway in BV2 murine microglial cells. Neurosci. Lett. 2008, 444, 264-269.
30. Zheng, J.; Hu, J.D.; Huang, Y.; Chen, B.Y. Effects of baicalin on proliferation and apoptosis of adriamycin-resistant human leukemia HL-60/ADR cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2009, 17, 1198-1202.
31. Aggarwal, B.B. Nuclear factor-jB: The enemy within. Cancer Cell 2004, 6, 203-206.
32. Salmena, L.; Carracedo, A.; Pandolfi, P.P. Tenets of PTEN tumor suppression. Cell 2008, 133, 403-414.
33. Maehama, T.; Dixon, J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273, 13375-13378.